JP2022103980A - Composition for oral cavity - Google Patents
Composition for oral cavity Download PDFInfo
- Publication number
- JP2022103980A JP2022103980A JP2020218921A JP2020218921A JP2022103980A JP 2022103980 A JP2022103980 A JP 2022103980A JP 2020218921 A JP2020218921 A JP 2020218921A JP 2020218921 A JP2020218921 A JP 2020218921A JP 2022103980 A JP2022103980 A JP 2022103980A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- amino acid
- oralis
- sugar
- oral composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 210000000214 mouth Anatomy 0.000 title abstract description 19
- 229940024606 amino acid Drugs 0.000 claims abstract description 45
- 235000001014 amino acid Nutrition 0.000 claims abstract description 45
- 150000001413 amino acids Chemical class 0.000 claims abstract description 44
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 27
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 27
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 24
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 22
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 22
- 239000004220 glutamic acid Substances 0.000 claims abstract description 22
- 229940009098 aspartate Drugs 0.000 claims abstract description 13
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 13
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004471 Glycine Substances 0.000 claims abstract description 12
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims abstract description 12
- 235000004279 alanine Nutrition 0.000 claims abstract description 12
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract description 9
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000013930 proline Nutrition 0.000 claims abstract description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims abstract description 7
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 7
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000004400 serine Nutrition 0.000 claims abstract description 7
- 239000004474 valine Substances 0.000 claims abstract description 7
- 235000014393 valine Nutrition 0.000 claims abstract description 7
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 6
- 235000000346 sugar Nutrition 0.000 claims description 37
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 14
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 14
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 10
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 10
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 10
- 229930182830 galactose Natural products 0.000 claims description 10
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 150000004677 hydrates Chemical class 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 241000194025 Streptococcus oralis Species 0.000 abstract description 10
- 229930195712 glutamate Natural products 0.000 abstract description 2
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- -1 alkali metal salts Chemical class 0.000 description 30
- 241000894006 Bacteria Species 0.000 description 16
- 235000014113 dietary fatty acids Nutrition 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000000194 fatty acid Substances 0.000 description 13
- 229930195729 fatty acid Natural products 0.000 description 13
- 239000012488 sample solution Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 7
- 229920001542 oligosaccharide Polymers 0.000 description 7
- 150000008163 sugars Chemical class 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 6
- 229960001375 lactose Drugs 0.000 description 6
- 150000002482 oligosaccharides Chemical class 0.000 description 6
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 5
- 235000013923 monosodium glutamate Nutrition 0.000 description 5
- 239000004223 monosodium glutamate Substances 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- WTWSHHITWMVLBX-DKWTVANSSA-M sodium;(2s)-2-aminobutanedioate;hydron Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC(O)=O WTWSHHITWMVLBX-DKWTVANSSA-M 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000002280 amphoteric surfactant Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000001848 Salivary Proteins and Peptides Human genes 0.000 description 3
- 108010029987 Salivary Proteins and Peptides Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 239000007621 bhi medium Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000002925 dental caries Diseases 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- 229960001021 lactose monohydrate Drugs 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229910001631 strontium chloride Inorganic materials 0.000 description 2
- AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- SVIJYLPSHPPVQF-UHFFFAOYSA-N 2-[2,2-diaminoethyl(dodecyl)amino]acetic acid Chemical compound CCCCCCCCCCCCN(CC(N)N)CC(O)=O SVIJYLPSHPPVQF-UHFFFAOYSA-N 0.000 description 1
- TXBCBTDQIULDIA-UHFFFAOYSA-N 2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)CO TXBCBTDQIULDIA-UHFFFAOYSA-N 0.000 description 1
- PTJWCLYPVFJWMP-UHFFFAOYSA-N 2-[[3-hydroxy-2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)COCC(CO)(CO)CO PTJWCLYPVFJWMP-UHFFFAOYSA-N 0.000 description 1
- HKKXJKUATKEWDT-UHFFFAOYSA-N 2-ethyl-2-(tetradecylamino)butanoic acid Chemical compound C(CCCCCCCCCCCCC)NC(C(=O)O)(CC)CC HKKXJKUATKEWDT-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical compound CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000972672 Phellodendron Species 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- JVWLUVNSQYXYBE-UHFFFAOYSA-N Ribitol Natural products OCC(C)C(O)C(O)CO JVWLUVNSQYXYBE-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000194026 Streptococcus gordonii Species 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- OBHAIFOMZXGPIA-DFWYDOINSA-N [Na].CN[C@@H](C)C(O)=O Chemical compound [Na].CN[C@@H](C)C(O)=O OBHAIFOMZXGPIA-DFWYDOINSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 229910000394 calcium triphosphate Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- NFCRBQADEGXVDL-UHFFFAOYSA-M cetylpyridinium chloride monohydrate Chemical compound O.[Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 NFCRBQADEGXVDL-UHFFFAOYSA-M 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229940073499 decyl glucoside Drugs 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 108010000165 exo-1,3-alpha-glucanase Proteins 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229940070818 glycyrrhizate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940031957 lauric acid diethanolamide Drugs 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940074096 monoolein Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- SCZVXVGZMZRGRU-UHFFFAOYSA-N n'-ethylethane-1,2-diamine Chemical class CCNCCN SCZVXVGZMZRGRU-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229960000414 sodium fluoride Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- SLBXZQMMERXQAL-UHFFFAOYSA-M sodium;1-dodecoxy-4-hydroxy-1,4-dioxobutane-2-sulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O SLBXZQMMERXQAL-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 description 1
- 229960002799 stannous fluoride Drugs 0.000 description 1
- FVRNDBHWWSPNOM-UHFFFAOYSA-L strontium fluoride Chemical compound [F-].[F-].[Sr+2] FVRNDBHWWSPNOM-UHFFFAOYSA-L 0.000 description 1
- 229910001637 strontium fluoride Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- VXYADVIJALMOEQ-UHFFFAOYSA-K tris(lactato)aluminium Chemical compound CC(O)C(=O)O[Al](OC(=O)C(C)O)OC(=O)C(C)O VXYADVIJALMOEQ-UHFFFAOYSA-K 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Abstract
Description
本発明は、口腔用組成物に関する。 The present invention relates to an oral composition.
口腔内において多くの細菌は、口腔内に浮遊しているか、バイオフィルムと呼ばれる細菌の凝集体に存在している。バイオフィルムは物理的な作用にも化学的な作用にも耐性を有しているため、バイオフィルムを除去することは、浮遊している細菌の除去と比較して困難である。 Many bacteria in the oral cavity are either floating in the oral cavity or present in bacterial aggregates called biofilms. Because biofilms are resistant to both physical and chemical action, removing biofilms is more difficult than removing floating bacteria.
口腔内に浮遊する細菌が歯牙や口腔粘膜表面に付着する機序に関しては、古くから研究され種々の知見が得られている。バイオフィルムの形成阻害を効果的に実施するためには、清潔な歯面に短時間で付着して初期プラークを形成する細菌である早期定着細菌の歯面への付着を防止することが重要と考えられている。早期定着細菌は、唾液タンパクと結合するレセプターを有しており、特定の唾液蛋白と結合すると付着を促進することが知られている。この唾液蛋白は、高プロリン蛋白と高プロリン糖蛋白に大別される。前者のレセプターを有する代表的な細菌としては、Streptococcus mutans、Streptococcus gordonii、Porphyromonas gingivalisなどが知られており、後者のレセプターを有する代表的な細菌としては、Staphylococcus aureus、Fusobacterium nucleatum、Streptococcus oralisなどが知られている。そのため、これらの二つの菌群に対して有効な付着防止効果を有する技術の開発が必要とされている。例えば、特許文献1には、水素添加処理したリン脂質を必須成分とするリポソームを含有する組成物を使用することにより、Streptococcus mutansやStaphylococcus aureusなどの細菌の口腔内組織への付着及び増殖を防止する技術が開示されている。 The mechanism by which bacteria floating in the oral cavity adhere to the surface of teeth and oral mucosa has been studied for a long time and various findings have been obtained. In order to effectively inhibit the formation of biofilm, it is important to prevent the early colonization bacteria, which are bacteria that adhere to clean tooth surfaces in a short time and form initial plaque, to adhere to the tooth surface. It is considered. Early colonization bacteria have receptors that bind to salivary proteins and are known to promote attachment when bound to specific salivary proteins. This salivary protein is roughly classified into high proline protein and high proline glycoprotein. Streptococcus mutans, Streptococcus gordonii, Porphyromonas gingivalis, etc. are known as typical bacteria having the former receptor, and Staphylococcus aureus, Fusobacterium nucleatum, Streptococcus oralis, etc. are known as typical bacteria having the latter receptor. Has been done. Therefore, it is necessary to develop a technique having an effective adhesion prevention effect against these two bacterial groups. For example, Patent Document 1 prevents bacteria such as Streptococcus mutans and Staphylococcus aureus from adhering to and proliferating in oral tissues by using a composition containing liposomes containing hydrogenated phospholipids as an essential component. The technology to be used is disclosed.
本発明者らの鋭意研究の結果、う蝕歴がない人は、う蝕歴の有る人と比較して、口腔内におけるStreptococcus oralis(以下、S.オラリスと記載する。)の濃度が高いという知見が得られた。この知見から、健康な口腔環境を確保する観点において、口腔内のS.オラリス濃度を高めることが重要であることが示唆される。 As a result of diligent research by the present inventors, it is said that those who have no history of caries have a higher concentration of Streptococcus oralis (hereinafter referred to as S. olaris) in the oral cavity than those who have a history of caries. Findings were obtained. From this finding, from the viewpoint of ensuring a healthy oral environment, S. It is suggested that it is important to increase the concentration of Oralis.
この発明は、上記知見に基づいてなされたものであり、その目的は、口腔内におけるS.オラリス濃度を高めることにある。 The present invention has been made based on the above findings, and an object thereof is S. cerevisiae in the oral cavity. The purpose is to increase the concentration of Oralis.
上記課題を解決する口腔用組成物は、アミノ酸と、重合度が1以上10以下の糖とを含有する口腔用組成物であって、前記アミノ酸は、アスパラギン酸、アスパラギン酸塩、グルタミン酸、グルタミン酸塩、アラニン、プロリン、セリン、バリン、及びグリシンから選ばれる少なくとも一種である。 The oral composition that solves the above-mentioned problems is an oral composition containing an amino acid and a sugar having a degree of polymerization of 1 or more and 10 or less, and the amino acid is aspartic acid, aspartate, glutamic acid, glutamic acid. , Alanine, proline, serine, valine, and glycine.
上記口腔用組成物において、前記アミノ酸は、アスパラギン酸、アスパラギン酸塩、グルタミン酸、グルタミン酸塩、アラニン、及びグリシンから選ばれる少なくとも一種であることが好ましい。 In the oral composition, the amino acid is preferably at least one selected from aspartic acid, aspartate, glutamic acid, glutamic acid, alanine, and glycine.
上記口腔用組成物において、前記糖は、ラクトース、ガラクトース、ラフィノース、ガラクトオリゴ糖、及びそれらの水和物から選ばれる少なくとも一種であることが好ましい。 In the oral composition, the sugar is preferably at least one selected from lactose, galactose, raffinose, galactooligosaccharides, and hydrates thereof.
本発明によれば、口腔内におけるS.オラリス濃度を高めることができる。 According to the present invention, S. in the oral cavity. The concentration of Oralis can be increased.
以下、本発明の一実施形態を説明する。
本実施形態の口腔用組成物は、特定のアミノ酸と、特定の糖とを含有する。
(特定のアミノ酸)
口腔用組成物に含有される特定のアミノ酸は、アスパラギン酸、アスパラギン酸塩、グルタミン酸、グルタミン酸塩、アラニン、プロリン、セリン、バリン、及びグリシンから選ばれる少なくとも一種である。アスパラギン酸塩及びグルタミン酸塩の具体例としては、ナトリウム塩やカリウム塩等のアルカリ金属塩、マグネシウム塩やカルシウム塩等のアルカリ土類金属塩が挙げられる。
Hereinafter, an embodiment of the present invention will be described.
The oral composition of the present embodiment contains a specific amino acid and a specific sugar.
(Specific amino acid)
The particular amino acid contained in the oral composition is at least one selected from aspartic acid, aspartate, glutamic acid, glutamic acid, alanine, proline, serine, valine, and glycine. Specific examples of asparagate and glutamate include alkali metal salts such as sodium salt and potassium salt, and alkaline earth metal salts such as magnesium salt and calcium salt.
口腔用組成物は、上記の特定のアミノ酸のうちの一種のみを単独で含有するものであってもよいし、二種以上を組み合わせて含有するものであってもよい。なお、口腔用組成物は、特定のアミノ酸として、アスパラギン酸、アスパラギン酸塩、グルタミン酸、グルタミン酸塩、アラニン、及びグリシンから選ばれる少なくとも一種を含有することが特に好ましい。 The oral composition may contain only one of the above-mentioned specific amino acids alone, or may contain two or more of them in combination. It is particularly preferable that the oral composition contains at least one selected from aspartic acid, aspartate, glutamic acid, glutamic acid, alanine, and glycine as a specific amino acid.
口腔用組成物における特定のアミノ酸の含有量は、例えば、0.5~4質量%であり、好ましくは1.5~3質量%であり、より好ましくは1.5~2質量%である。
(特定の糖)
口腔用組成物に含有される特定の糖は、重合度が1以上10以下の糖である。特定の糖の種類としては、例えば、単糖、二糖、三糖以上のオリゴ糖、糖アルコールが挙げられる。
The content of the specific amino acid in the oral composition is, for example, 0.5 to 4% by mass, preferably 1.5 to 3% by mass, and more preferably 1.5 to 2% by mass.
(Specific sugar)
The specific sugar contained in the oral composition is a sugar having a degree of polymerization of 1 or more and 10 or less. Specific sugar types include, for example, monosaccharides, disaccharides, oligosaccharides of trisaccharides or higher, and sugar alcohols.
単糖としては、例えば、ガラクトース、マンノース、アラビノース、及びそれらの水和物が挙げられる。
二糖としては、例えば、マルトース、スクロース、ラクトース、及びそれらの水和物が挙げられる。
Examples of monosaccharides include galactose, mannose, arabinose, and hydrates thereof.
Examples of the disaccharide include maltose, sucrose, lactose, and hydrates thereof.
オリゴ糖としては、例えば、ラフィノース、ガラクトオリゴ糖、大豆オリゴ糖、乳果オリゴ糖、キシロオリゴ糖、ゲンチオオリゴ糖、マルトオリゴ糖、環状オリゴ糖、ミルクオリゴ糖、及びそれらの水和物が挙げられる。 Examples of oligosaccharides include raffinose, galactooligosaccharides, soybean oligosaccharides, milk fruit oligosaccharides, xylooligosaccharides, gentiooligosaccharides, maltooligosaccharides, cyclic oligosaccharides, milk oligosaccharides, and hydrates thereof.
糖アルコールとしては、例えば、上記の単糖、二糖、又はオリゴ糖を工業的に還元処理して得られるものが挙げられ、例えば、ソルビトール、ラクチトール、還元イソマルツロース(パラチニット(登録商標))、トレイトール、ペンタエリスリトール、ジペンタエリスリトール、トリペンタエリスリトール、アラビトール、リビトール、マンニトール、スレイトール、グリトール、タリトール、ガアリトール、アルトリトール、ドルシトール、イディトール、イノシトール、マルチトール、イソマルチトール、ラクチトール、ツラニトールが挙げられる。 Examples of the sugar alcohol include those obtained by industrially reducing the above-mentioned monosaccharides, disaccharides, or oligosaccharides, and examples thereof include sorbitol, lactitol, and reduced isomaltitol (Palatinit (registered trademark)). , Traitol, pentaerythritol, dipentaerythritol, tripentaerythritol, arabitol, ribitol, mannitol, thraitol, gritol, taritol, gaaritol, altritor, dolsitol, iditol, inositol, maltitol, isomartitol, lactitol, turanitol. Will be.
口腔用組成物は、上記の特定の糖のうちの一種のみを単独で含有するものであってもよいし、二種以上を組み合わせて含有するものであってもよい。なお、口腔用組成物は、特定の糖として、ラクトース、ガラクトース、ラフィノース、ガラクトオリゴ糖、及びそれらの水和物から選ばれる少なくとも一種を含有することが特に好ましい。 The oral composition may contain only one of the above-mentioned specific sugars alone, or may contain two or more of them in combination. In addition, it is particularly preferable that the oral composition contains at least one selected from lactose, galactose, raffinose, galactooligosaccharide, and hydrates thereof as a specific sugar.
口腔用組成物における特定の糖の含有量は、例えば、0.5~4質量%であり、好ましくは1.5~3質量%であり、より好ましくは1.5~2質量%である。また、口腔用組成物における特定のアミノ酸に対する特定の糖の質量比(特定の糖/特定のアミノ酸)は、例えば、0.5~4であり、好ましくは0.5~2であり、より好ましくは1~2である。 The content of the specific sugar in the oral composition is, for example, 0.5 to 4% by mass, preferably 1.5 to 3% by mass, and more preferably 1.5 to 2% by mass. The mass ratio of a specific sugar to a specific amino acid (specific sugar / specific amino acid) in the oral composition is, for example, 0.5 to 4, preferably 0.5 to 2, more preferably. Is 1-2.
(特定のアミノ酸と特定の糖の組み合わせ)
口腔用組成物は、特定のアミノ酸として、アスパラギン酸、及びアスパラギン酸塩から選ばれる少なくとも一種を含有するとともに、特定の糖として、ラクトース、ガラクトース、ラフィノース、及びガラクトオリゴ糖から選ばれる少なくとも一種を含有することが好ましい。また、口腔用組成物は、特定のアミノ酸として、グルタミン酸、及びグルタミン酸塩から選ばれる少なくとも一種を含有するとともに、特定の糖として、ガラクトオリゴ糖を含有することが好ましい。
(Combination of specific amino acids and specific sugars)
The oral composition contains at least one selected from aspartic acid and aspartate as a specific amino acid, and at least one selected from lactose, galactose, raffinose, and galactooligosaccharide as a specific sugar. Is preferable. Further, the oral composition preferably contains at least one selected from glutamic acid and glutamic acid salt as a specific amino acid, and preferably contains galactooligosaccharide as a specific sugar.
(適用形態、用途、及び剤形)
口腔用組成物の適用形態は、特に限定されず、例えば、医薬品、医薬部外品、化粧品として使用することができる。口腔用組成物の用途としては、公知のものを適宜採用することができ、例えば、練歯磨剤、洗口剤、含漱剤、液体歯磨剤、バイオフィルム分散剤、口臭予防剤、歯茎マッサージ剤、口腔用湿潤付与剤、舌苔除去剤、口腔内塗布剤、口腔殺菌剤、咽喉殺菌剤、口腔咽喉剤、歯周病治療剤、義歯装着剤、義歯コーティング剤、義歯安定化剤、義歯保存剤、義歯洗浄剤、インプラントケア剤が挙げられる。
(Applicable form, application, and dosage form)
The application form of the oral composition is not particularly limited, and can be used as, for example, a pharmaceutical product, a quasi-drug, or a cosmetic product. As the use of the oral composition, known ones can be appropriately adopted, for example, a denture polish, a mouthwash, a moisturizer, a liquid dentifrice, a biofilm dispersant, a mouth odor preventive agent, and a gum massage agent. , Oral moisturizer, tongue moss remover, oral coating agent, oral sterilizer, throat sterilizer, oral throat agent, periodontal disease treatment agent, denture mounting agent, denture coating agent, denture stabilizer, denture preservative , Denture cleaning agents, implant care agents.
口腔用組成物の剤形は、特に限定されず、例えば、水、アルコール等の溶媒を含有することにより、軟膏剤、ペースト剤、パスタ剤、スプレー剤、ジェル剤、液剤、懸濁・乳化剤、ガム剤等に適用することができる。 The dosage form of the oral composition is not particularly limited, and for example, by containing a solvent such as water or alcohol, an ointment, a paste, a pasta, a spray, a gel, a liquid, a suspension / emulsifier, etc. It can be applied to gum agents and the like.
溶媒として用いられる水の種類は特に限定されず、例えば、蒸留水、純水、超純水、精製水、水道水等を用いることができる。溶媒として用いられるアルコールの種類は特に限定されず、例えば、エタノールを用いることができる。水とアルコールを混合して用いることもできる。 The type of water used as the solvent is not particularly limited, and for example, distilled water, pure water, ultrapure water, purified water, tap water and the like can be used. The type of alcohol used as the solvent is not particularly limited, and for example, ethanol can be used. Water and alcohol can be mixed and used.
口腔用組成物が液状に構成されている場合において、水等の溶媒の含有量は、例えば、60~99.8質量%であることが好ましく、70~90質量%であることがより好ましい。 When the oral composition is composed of a liquid, the content of the solvent such as water is preferably, for example, 60 to 99.8% by mass, more preferably 70 to 90% by mass.
(その他成分)
口腔用組成物は、適用目的、形態、用途等に応じて、前述した成分以外のその他成分を含有してもよい。その他成分としては、例えば、抗菌剤、抗炎症剤、香料、湿潤剤、界面活性剤、研磨剤、アルコール類、増粘剤、甘味成分、薬用成分、着色剤、安定化剤、pH調整剤が挙げられる。その他成分は、口腔用組成物に配合される公知のものを使用することができる。口腔用組成物は、上記のその他成分のそれぞれについて、一種のみを単独で含有するものであってもよいし、二種以上を組み合わせて含有するものであってもよい。
(Other ingredients)
The oral composition may contain other components other than the above-mentioned components depending on the purpose of application, form, use and the like. Other ingredients include, for example, antibacterial agents, anti-inflammatory agents, fragrances, wetting agents, surfactants, abrasives, alcohols, thickeners, sweetening ingredients, medicinal ingredients, colorants, stabilizers, and pH adjusters. Can be mentioned. As the other components, known ones to be blended in the oral composition can be used. The oral composition may contain only one kind of each of the above other components alone, or may contain two or more kinds in combination.
抗菌剤としては、例えば、塩化セチルピリジニウム、パラベン、安息香酸ナトリウム、トリクロサン、塩酸クロルヘキシジン、イソプロピルメチルフェノール、塩化ベンザルコニウム、塩化ベンゼトニウム、ヒノキチオールが挙げられる。 Examples of the antibacterial agent include cetylpyridinium chloride, paraben, sodium benzoate, triclosan, chlorhexidine hydrochloride, isopropylmethylphenol, benzalkonium chloride, benzethonium chloride, and hinokithiol.
抗炎症剤としては、例えば、グリチルリチン酸塩、トラネキサム酸、ε-アミノカプロン酸、オウバクエキスが挙げられる。
香料としては、例えば、アネトール、オイゲノール、カルボン、ウインターグリーン、サリチル酸メチル、チモール、丁字油、セージ油、オシメン油、シトロネロールが挙げられる。
Examples of the anti-inflammatory agent include glycyrrhizate, tranexamic acid, ε-aminocaproic acid, and Phellodendron amur extract.
Examples of the fragrance include anethole, eugenol, carboxylic, winter green, methyl salicylate, timol, clove oil, sage oil, ossimen oil, and citronellol.
界面活性剤としては、例えば、非イオン性界面活性剤、アニオン界面活性剤、両性界面活性剤が挙げられる。
非イオン性界面活性剤としては、例えば、ショ糖脂肪酸エステル、マルトース脂肪酸エステル等の糖脂肪酸エステル、マルチトール脂肪酸エステル等の糖アルコール脂肪酸エステル、モノラウリン酸ソルビタン等のソルビタン脂肪酸エステル、ポリオキシエチレンソルビタンモノラウレート、ポリオキシエチレンソルビタンモノステアレート等のポリオキシエチレンソルビタン脂肪酸エステル、ラウリン酸ジエタノールアミド等の脂肪酸アルカノールアミド、ポリオキシエチレンステアリルエーテル、ポリオキシエチレンオレイルエーテル等のポリオキシエチレンアルキルエーテル、モノオレイン酸ポリエチレングリコール、モノラウリン酸ポリエチレングリコール等のポリエチレングリコール脂肪酸エステル、ラウリルグルコシド、デシルグルコシド等のアルキルグルコシド、ポリグリセリン脂肪酸エステル、ポリオキシエチレングリセリン脂肪酸エステル、ポリオキシエチレン脂肪酸エステル、アルキルグルコシド類、ポリオキシエチレン硬化ヒマシ油、グリセリン脂肪酸エステル、ポリオキシエチレンプロピレンブロックコポリマーが挙げられる。
Examples of the surfactant include nonionic surfactants, anionic surfactants, and amphoteric surfactants.
Examples of the nonionic surfactant include sucrose fatty acid ester, sugar fatty acid ester such as maltose fatty acid ester, sugar alcohol fatty acid ester such as maltitol fatty acid ester, sorbitan fatty acid ester such as monolauric acid sorbitan, and polyoxyethylene sorbitan mono. Polyoxyethylene sorbitan fatty acid esters such as laurate and polyoxyethylene sorbitan monostearate, fatty acid alkanolamides such as lauric acid diethanolamide, polyoxyethylene alkyl ethers such as polyoxyethylene stearyl ether and polyoxyethylene oleyl ether, and monoolein. Polyethylene glycol fatty acid esters such as polyethylene glycol acid and polyethylene glycol monolaurate, alkyl glucosides such as lauryl glucoside and decyl glucoside, polyglycerin fatty acid ester, polyoxyethylene glycerin fatty acid ester, polyoxyethylene fatty acid ester, alkyl glucosides, polyoxyethylene Examples include cured castor oil, glycerin fatty acid ester, and polyoxyethylene propylene block copolymer.
アニオン界面活性剤としては、例えば、ラウリル硫酸ナトリウム、ポリオキシエチレンラウリルエーテル硫酸ナトリウム等の硫酸エステル塩、ラウリルスルホコハク酸ナトリウム、ポリオキシエチレンラウリルエーテルスルホコハク酸ナトリウム等のスルホコハク酸塩、ココイルサルコシンナトリウム、ラウロイルメチルアラニンナトリウム等のアシルアミノ酸塩、ココイルメチルタウリンナトリウムが挙げられる。 Examples of the anionic surfactant include sulfate ester salts such as sodium lauryl sulfate and sodium polyoxyethylene lauryl ether sulfate, sulfosuccinates such as sodium lauryl sulfosuccinate and sodium polyoxyethylene lauryl ether sulfosuccinate, cocoyl sarcosine sodium and lauroyl. Examples thereof include acyl amino acid salts such as sodium methylalanine and sodium cocoylmethyltaurine.
両性界面活性剤としては、例えば、Nーラウリルジアミノエチルグリシン、Nーミリスチルジエチルグリシン等のアミノ酸型両性界面活性剤、アルキルジメチルアミノ酢酸ベタイン、N-アルキル-N’-カルボキシメチル-N’-ヒドロキシエチルエチレンジアミン塩、及び2-アルキル-N-カルボキシメチル-N-ヒドロキシエチルイミダゾリニウムベタイン等のベタイン系両性界面活性剤が挙げられる。 Examples of the amphoteric surfactant include amino acid type amphoteric surfactants such as N-lauryldiaminoethylglycine and N-myristyldiethylglycine, alkyldimethylaminoacetate betaine, and N-alkyl-N'-carboxymethyl-N'-hydroxy. Examples thereof include betaine-based amphoteric surfactants such as ethylethylenediamine salt and 2-alkyl-N-carboxymethyl-N-hydroxyethylimidazolinium betaine.
研磨剤としては、例えば、炭酸カルシウム、炭酸マグネシウム、第二リン酸カルシウム、第三リン酸カルシウム、リン酸マグネシウム、シリカ、ゼオライト、メタリン酸ナトリウム、水酸化アルミニウム、水酸化マグネシウム、ピロリン酸カルシウム、ベンガラ、硫酸カルシウム、無水ケイ酸が挙げられる。 Examples of the polishing agent include calcium carbonate, magnesium carbonate, dicalcium phosphate, calcium triphosphate, magnesium phosphate, silica, zeolite, sodium metaphosphate, aluminum hydroxide, magnesium hydroxide, calcium pyrophosphate, red iron oxide, calcium sulfate, and anhydrous. Calcium can be mentioned.
アルコール類としては、例えば、エチルアルコール、ラウリルアルコール、ミリスチルアルコール等が挙げられる。
増粘剤としては、例えば、ポリアクリル酸ナトリウム、カラギーナン、カルボキシメチルセルロースナトリウム、アルギン酸ナトリウム、キサンタンガム、ヒドロキシエチルセルロース、ヒドロキシプロピルメチルセルロース、メチルセルロース、アルギン酸プロピレングリコールエステルが挙げられる。
Examples of alcohols include ethyl alcohol, lauryl alcohol, myristyl alcohol and the like.
Examples of the thickener include sodium polyacrylate, carrageenan, sodium carboxymethyl cellulose, sodium alginate, xanthan gum, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, and propylene glycol alginate.
薬用成分としては、例えば、モノフルオロリン酸ナトリウム、フッ化ナトリウム、フッ化第1スズ、フッ化ストロンチウム等のフッ化物、ピロリン酸ナトリウムやポリリン酸ナトリウム等の縮合リン酸塩、リン酸一水素ナトリウム、リン酸三ナトリウム等のリン酸塩、アスコルビン酸、アスコルビン酸ナトリウム、塩酸ピリドキシン、トコフェロール酢酸エステル等のビタミン剤、デキストラナーゼ、ムタナーゼ等のグルカナーゼ酵素、プロテアーゼ、リゾチーム等の分解酵素、塩化亜鉛、クエン酸亜鉛、塩化ストロンチウム、硝酸カリウム等の無機塩類、クロロフィル、グリセロホスフェート等のキレート性化合物、脂を溶解するポリエチレングリコール等、塩化ナトリウム、乳酸アルミニウム、塩化ストロンチウムが挙げられる。 Examples of the medicinal component include fluorides such as sodium monofluorophosphate, sodium fluoride, stannous fluoride and strontium fluoride, condensed phosphates such as sodium pyrophosphate and sodium polyphosphate, and sodium monohydrogen phosphate. , Phosphates such as trisodium phosphate, ascorbic acid, sodium ascorbate, pyridoxin hydrochloride, tocopherol acetate and other vitamins, dextranase, glucanase enzymes such as mutanase, proteases, degrading enzymes such as lysoteam, zinc chloride, Examples thereof include inorganic salts such as zinc citrate, strontium chloride and potassium nitrate, chelating compounds such as chlorophyll and glycerophosphate, polyethylene glycol which dissolves fat, sodium chloride, aluminum lactate and strontium chloride.
着色剤としては、例えば、緑色1号、青色1号、黄色4号等の法定色素、酸化チタン等が挙げられる。
安定化剤としては、例えば、エデト酸ナトリウム、チオ硫酸ナトリウム、亜硫酸ナトリウム、乳酸カルシウム、ラノリン、トリアセチン、ヒマシ油、硫酸マグネシウム等が挙げられる。
Examples of the colorant include legal dyes such as Green No. 1, Blue No. 1, and Yellow No. 4, titanium oxide, and the like.
Examples of the stabilizer include sodium edetate, sodium thiosulfate, sodium sulfite, calcium lactate, lanolin, triacetin, castor oil, magnesium sulfate and the like.
pH調整剤としては、例えば、クエン酸、リンゴ酸、乳酸、酒石酸、酢酸、リン酸、ピロリン酸、グリセロリン酸、並びにこれらのカリウム塩、ナトリウム塩及びアンモニウム塩等の各種塩、水酸化ナトリウム等が挙げられる。口腔用組成物は、pH調整剤を配合することにより、pHが4~9、特に5~7の範囲になるように調整されていることが好ましい。 Examples of the pH adjuster include citric acid, malic acid, lactic acid, tartrate acid, acetic acid, phosphoric acid, pyrophosphate, glycerophosphate, various salts such as potassium salt, sodium salt and ammonium salt, sodium hydroxide and the like. Can be mentioned. The oral composition is preferably adjusted so that the pH is in the range of 4 to 9, particularly 5 to 7, by adding a pH adjuster.
次に、本実施形態の作用について記載する。
詳細は省略するが、う蝕歴の有る対象群と、う蝕歴がない対象群との間で唾液中のS.オラリス濃度を比較したところ、う蝕歴がない対象群の方がS.オラリス濃度が有意に高い結果が得られた。この結果から、健康な口腔環境を確保する観点において、口腔内のS.オラリス濃度を高めることが重要であると考えられる。そのメカニズムは、以下のように推測できる。
Next, the operation of this embodiment will be described.
Although the details are omitted, the S.I. When the olaris concentration was compared, the subject group with no history of caries was found to be S. The results showed that the concentration of Oralis was significantly high. From this result, from the viewpoint of ensuring a healthy oral environment, S. It is considered important to increase the concentration of Oralis. The mechanism can be inferred as follows.
早期定着細菌は、歯面に付着して初期プラークを形成する細菌であり、バイオフィルムを形成する病原菌の歯面への付着を仲介する。早期定着細菌のなかでも、S.オラリスは、バイオフィルムを形成する病原菌に対する付着性が弱く、歯面におけるS.オラリスが定着した部分は、他の早期定着細菌が付着した部分と比較して、病原菌が付着し難い部位になる。 Early colonization bacteria are bacteria that attach to the tooth surface to form early plaques and mediate the attachment of biofilm-forming pathogens to the tooth surface. Among the early colonization bacteria, S. Oralis has weak adhesion to biofilm-forming pathogens and has S. cerevisiae on the tooth surface. The part where the alaris has settled becomes a part where the pathogen is less likely to adhere as compared with the part where the other early colonizing bacteria have adhered.
そのため、口腔内におけるS.オラリス濃度が上昇すると、歯面に早期定着細菌が定着した際に、早期定着細菌が定着した部分におけるS.オラリスが定着した部分の比率が増加する。換言すると、口腔内におけるS.オラリス濃度が上昇することにより、病原菌が付着しやすい他の早期定着細菌の歯面への定着が競合的に阻害される。病原菌が付着しやすい他の早期定着細菌の歯面への定着が抑制される結果、バイオフィルムの形成が抑制されて、健康な口腔環境が得られやすくなる。 Therefore, in the oral cavity, S. When the concentration of Oralis increased, when the early colonizing bacteria were established on the tooth surface, S.I. The proportion of the part where Oralis has settled increases. In other words, S. in the oral cavity. The increase in the concentration of Oralis competitively inhibits the colonization of other early colonization bacteria to which pathogens are likely to adhere to the tooth surface. As a result of suppressing the colonization of other early colonization bacteria to which pathogens tend to adhere to the tooth surface, the formation of biofilm is suppressed, and a healthy oral environment can be easily obtained.
本実施形態の口腔用組成物は、S.オラリスを口腔内にて増殖させることができる。本実施形態の口腔用組成物は、S.オラリスを口腔内にて増殖させる効果に基づいてバイオフィルムの形成を抑制する効果が期待できる。 The oral composition of the present embodiment is S.I. Oralis can be grown in the oral cavity. The oral composition of the present embodiment is S.I. An effect of suppressing the formation of biofilm can be expected based on the effect of growing Oralis in the oral cavity.
次に、本実施形態の効果について記載する。
(1)口腔用組成物は、特定のアミノ酸と、重合度が1以上10以下の特定の糖とを含有する。特定のアミノ酸は、アスパラギン酸、アスパラギン酸塩、グルタミン酸、グルタミン酸塩、アラニン、プロリン、セリン、バリン、及びグリシンから選ばれる少なくとも一種である。上記構成によれば、S.オラリスを口腔内にて増殖させることができる。
Next, the effect of this embodiment will be described.
(1) The oral composition contains a specific amino acid and a specific sugar having a degree of polymerization of 1 or more and 10 or less. The particular amino acid is at least one selected from aspartic acid, aspartate, glutamic acid, glutamic acid, alanine, proline, serine, valine, and glycine. According to the above configuration, S. Oralis can be grown in the oral cavity.
(2)特定のアミノ酸は、アスパラギン酸、アスパラギン酸塩、グルタミン酸、グルタミン酸塩、アラニン、及びグリシンから選ばれる少なくとも一種である。この場合には、S.オラリスを口腔内にて増殖させる効果がより顕著に得られる。 (2) The specific amino acid is at least one selected from aspartic acid, aspartate, glutamic acid, glutamic acid, alanine, and glycine. In this case, S. The effect of growing Oralis in the oral cavity is more remarkable.
(3)特定の糖は、ラクトース、ガラクトース、ラフィノース、ガラクトオリゴ糖、及びそれらの水和物から選ばれる少なくとも一種である。この場合には、S.オラリスを口腔内にて増殖させる効果がより顕著に得られる。 (3) The specific sugar is at least one selected from lactose, galactose, raffinose, galactooligosaccharides, and hydrates thereof. In this case, S. The effect of growing Oralis in the oral cavity is more remarkable.
(4)特定のアミノ酸は、アスパラギン酸、及びアスパラギン酸塩から選ばれる少なくとも一種である。特定の糖は、ガラクトース、ラフィノース、及びガラクトオリゴ糖から選ばれる少なくとも一種である。この場合には、S.オラリスを口腔内にて増殖させる効果が更に顕著に得られる。 (4) The specific amino acid is at least one selected from aspartic acid and aspartate. The particular sugar is at least one selected from galactose, raffinose, and galactooligosaccharides. In this case, S. The effect of growing Oralis in the oral cavity is more remarkable.
(5)特定のアミノ酸は、グルタミン酸、及びグルタミン酸塩から選ばれる少なくとも一種である。特定の糖は、ガラクトオリゴ糖である。この場合には、S.オラリスを口腔内にて増殖させる効果が更に顕著に得られる。 (5) The specific amino acid is at least one selected from glutamic acid and glutamic acid salt. The specific sugar is a galactooligosaccharide. In this case, S. The effect of growing Oralis in the oral cavity is more remarkable.
本発明の口腔用組成物について、以下の実施例及び比較例に基づいてさらに詳細に説明する。なお、本発明は、以下の実施例の構成に限定されるものではない。
<試験1>
(S.オラリスの培養試験)
BHI培地(Brain Heart Infusion broth(BD社製))にてS.オラリスを培養した。培養液の波長660nmにおける濁度を測定した後、測定した濁度が0.1になるように培養液をBHI培地にて希釈して、これを菌液とした。S.オラリスとして、Streptococcus oralis spp. dentisani, tigurinusを用いた。
The oral composition of the present invention will be described in more detail based on the following examples and comparative examples. The present invention is not limited to the configuration of the following examples.
<Test 1>
(S. Oralis culture test)
In BHI medium (Brain Heart Infusion broth (manufactured by BD)), S. Oralis was cultured. After measuring the turbidity of the culture solution at a wavelength of 660 nm, the culture solution was diluted with BHI medium so that the measured turbidity became 0.1, and this was used as a bacterial solution. S. Streptococcus oralis spp. Denisani, tigurinus was used as the olaris.
BHI培地にアミノ酸及び糖を溶解させた実施例1~7及び比較例1~6のサンプル溶液を調製した。各サンプル溶液に用いたアミノ酸及び糖の種類は、表1に示すとおりである。各サンプル溶液におけるアミノ酸の濃度は、表1に示すとおりである。各サンプル溶液における糖の濃度は、20mg/mlとした。 Sample solutions of Examples 1 to 7 and Comparative Examples 1 to 6 in which amino acids and sugars were dissolved in BHI medium were prepared. The types of amino acids and sugars used in each sample solution are as shown in Table 1. The amino acid concentrations in each sample solution are as shown in Table 1. The concentration of sugar in each sample solution was 20 mg / ml.
96穴プレートのウェルに菌液100μl及びサンプル溶液100μlを添加し、37℃、嫌気条件にて24時間培養した。培養後、上清を取り除き、リン酸緩衝食塩水(PBS)にて11倍希釈したAlamar Blue溶液(Invitrogen社製)110μlを添加し、励起波長545nm、蛍光波長590nmにて蛍光強度を測定した。サンプル溶液未添加のコントロールの蛍光強度に対する相対値をS.オラリスの育成度として算出するとともに、算出した育成度を以下の評価基準で評価した。それらの結果を表1に示す。 100 μl of the bacterial solution and 100 μl of the sample solution were added to the wells of the 96-well plate, and the cells were cultured at 37 ° C. under anaerobic conditions for 24 hours. After culturing, the supernatant was removed, 110 μl of Alamar Blue solution (manufactured by Invitrogen) diluted 11-fold with phosphate buffered saline (PBS) was added, and the fluorescence intensity was measured at an excitation wavelength of 545 nm and a fluorescence wavelength of 590 nm. The relative value of the control to which the sample solution was not added with respect to the fluorescence intensity was set to S.I. It was calculated as the degree of growth of Oralis, and the calculated degree of growth was evaluated according to the following evaluation criteria. The results are shown in Table 1.
◎:10以上
○:5以上10未満
×:5未満
⊚: 10 or more ○: 5 or more and less than 10 ×: less than 5
<試験2>
次に、アミノ酸として、試験1において顕著な増殖促進効果を示したアスパラギン酸ナトリウム及びグルタミン酸ナトリウムを用いて、糖の種類を変更した場合におけるS.オラリスの育成度を測定した。試験方法は、各サンプル溶液に用いたアミノ酸及び糖の組み合わせを変更した点、及び各サンプル溶液におけるアミノ酸の濃度を全て20mg/mlとした点を除いて、試験1と同様である。各サンプル溶液に用いたアミノ酸及び糖の種類、並びに育成度の測定結果を表2に示す。
<Test 2>
Next, when sodium aspartate and monosodium glutamate, which showed a remarkable growth promoting effect in Test 1, were used as amino acids, the type of sugar was changed. The degree of growth of Oralis was measured. The test method is the same as in Test 1 except that the combination of amino acids and sugars used in each sample solution is changed and the concentrations of amino acids in each sample solution are all 20 mg / ml. Table 2 shows the types of amino acids and sugars used in each sample solution and the measurement results of the degree of growth.
次に、上記実施形態から把握できる技術的思想を以下に記載する。
(イ)前記アミノ酸は、アスパラギン酸、及びアスパラギン酸塩から選ばれる少なくとも一種であり、前記糖は、ラクトース、ガラクトース、ラフィノース、及びガラクトオリゴ糖から選ばれる少なくとも一種である前記口腔用組成物。
Next, the technical idea that can be grasped from the above embodiment is described below.
(A) The oral composition in which the amino acid is at least one selected from aspartic acid and aspartate, and the sugar is at least one selected from lactose, galactose, raffinose, and galactooligosaccharide.
(ロ)前記アミノ酸は、グルタミン酸、及びグルタミン酸塩から選ばれる少なくとも一種であり、前記糖は、ガラクトオリゴ糖である前記口腔用組成物。
(ハ)前記アミノ酸に対する前記糖の質量比(糖/アミノ酸)は、0.5~3である前記口腔用組成物。
(B) The oral composition in which the amino acid is at least one selected from glutamic acid and glutamic acid salt, and the sugar is a galactooligosaccharide.
(C) The oral composition having a mass ratio (sugar / amino acid) of the sugar to the amino acid of 0.5 to 3.
(ニ)Streptococcus oralisの増殖を促進する細菌増殖促進用組成物であって、アミノ酸と、重合度が1以上10以下の糖とを含有し、前記アミノ酸は、アスパラギン酸、アスパラギン酸塩、グルタミン酸、グルタミン酸塩、アラニン、プロリン、セリン、バリン、グリシンから選ばれる少なくとも一種であることを特徴とする細菌増殖促進用組成物。 (D) A composition for promoting bacterial growth that promotes the growth of Streptococcus oralis, which contains an amino acid and a sugar having a degree of polymerization of 1 or more and 10 or less, and the amino acids are aspartic acid, aspartate, glutamic acid, and the like. A composition for promoting bacterial growth, which is at least one selected from glutamic acid, alanine, proline, serine, valine, and glycine.
(ホ)唾液中のStreptococcus oralisの増殖を促進する細菌増殖促進方法であって、前記細菌増殖促進用組成物を唾液に添加することを特徴とする細菌増殖促進方法。 (E) A method for promoting bacterial growth that promotes the growth of Streptococcus oralis in saliva, which comprises adding the composition for promoting bacterial growth to saliva.
Claims (3)
前記アミノ酸は、アスパラギン酸、アスパラギン酸塩、グルタミン酸、グルタミン酸塩、アラニン、プロリン、セリン、バリン、及びグリシンから選ばれる少なくとも一種であることを特徴とする口腔用組成物。 An oral composition containing an amino acid and a sugar having a degree of polymerization of 1 or more and 10 or less.
The oral composition is characterized in that the amino acid is at least one selected from aspartic acid, aspartate, glutamic acid, glutamic acid, alanine, proline, serine, valine, and glycine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020218921A JP2022103980A (en) | 2020-12-28 | 2020-12-28 | Composition for oral cavity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020218921A JP2022103980A (en) | 2020-12-28 | 2020-12-28 | Composition for oral cavity |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022103980A true JP2022103980A (en) | 2022-07-08 |
Family
ID=82285271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020218921A Pending JP2022103980A (en) | 2020-12-28 | 2020-12-28 | Composition for oral cavity |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2022103980A (en) |
-
2020
- 2020-12-28 JP JP2020218921A patent/JP2022103980A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6038167B2 (en) | Compositions and methods for preventing and treating oral diseases | |
EP0049830B1 (en) | Mouthwash compositions comprising hexetidine and zinc salts for the synergistic inhibition of dental plaque | |
JP6751350B2 (en) | Oral care composition | |
AU2013408774B2 (en) | Prebiotic oral care methods using a saccharide | |
RU2416391C1 (en) | Composition for oral cavity care | |
JPH11255629A (en) | Composition for oral cavity | |
WO2015099152A1 (en) | Oral composition | |
CN114025773A (en) | Oral care compositions and methods of use | |
KR20160007049A (en) | Improved anti-inflammatory and germicidal composition for preventing or alleviating periodontal disease | |
CN115916352A (en) | Oral care compositions | |
JP2013151473A (en) | Composition for oral cavity | |
US5827503A (en) | Method and composition for treating periodontitis | |
JP2007169201A (en) | Composition for oral cavity | |
JP2022103980A (en) | Composition for oral cavity | |
JP2003246717A (en) | Composition for oral cavity | |
WO2022133234A1 (en) | Oral care compositions with amine flourides | |
WO2022145325A1 (en) | Composition for oral cavity | |
JPH06239723A (en) | Composition for oral cavity | |
JP3821037B2 (en) | Periodontal pathogen adhesion inhibitor and composition for oral cavity having periodontal pathogen adhesion inhibitory action | |
JPH07543B2 (en) | Toothpaste composition | |
EP0086290B1 (en) | Dental hygiene compositions and their production | |
AU2022280872A1 (en) | Oral care compositions | |
JP2006151876A (en) | Composition for preventing periodontal disease | |
JP2024005652A (en) | Oral composition | |
JP2023091841A (en) | oral composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20210406 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231215 |